Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Cenderitide

Peptide · Agonist of natriuretic peptide receptor A (NPR1) and natriuretic peptide receptor B (NPR2) · developed by Capricor

Phase 2 Most advanced trial (none active)

CAPR Developer

1 Registered trials

What is Cenderitide?

Cenderitide is a dual natriuretic peptide receptor agonist studied in heart failure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Peptide
Targets: natriuretic peptide receptor A (NPR1), natriuretic peptide receptor B (NPR2)
Mechanism: Agonist of natriuretic peptide receptor A (NPR1) and natriuretic peptide receptor B (NPR2)
Therapy area: Cardiovascular
Developer: Capricor Inc. (CAPR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 9NKZ9LYZ06

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02359227	Phase 2	Heart Failure	Completed	CAPR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Heart Failure

Other drugs acting on NPR1 / NPR2

Navepegritide FDA approved TransCon CNP FDA approved

More from Capricor

Deramiocel Phase 3

Sources

ClinicalTrials.gov NCT02359227

Updated Oct 3, 2026. Something wrong or missing? Report it on the CAPR page.

Follow CAPR, the company behind Cenderitide

See CAPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CAPR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z